Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Must-Have Wellness Gear: What to Purchase for Successful Exercises - 2The Response to Self-improvement: Embracing a Development Outlook
- 3Baikonur launch pad damaged after Russian Soyuz launch to International Space Station
- 4What you need to know about flu treatments as cases spike across the US
- 5Dominating the Art of Composing: Creator Bits of knowledge
- The Best Computer games Ever
- Eleven Creations And Developments That Steered History
- Lilly becomes first healthcare firm to join trillion-dollar club, Wall Street reacts
- Bestselling author Colleen Hoover reveals cancer journey
- Spain and Catholic Church agree to compensate sex abuse victims
- The Significance of Health Projects in Senior Protection.
- Recent studies prove the ancient practice of nasal irrigation is effective at fighting the common cold
- 'We need everyone,' wounded reservist urges Knesset panel to advance haredi draft law
- Roche breast cancer pill cuts risk of disease recurrence by 30% in trial
